Why Valeant Pharmaceuticals Intl Inc. Will Fail to Re-Invent Itself

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) had a horrible year, and I believe the stock is far from rallying.

The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) had an abysmal year as the stock plummeted 86%. The company wants to re-invent itself to become a dominant player in the pharmaceutical scene again.

There were huge changes made this year as ex-CEO Michael Pearson stepped out and Joseph Papa stepped in. Joseph Papa is an excellent choice as the new CEO, and he’s got a ton of incentive to bring the company out of the gutter, but I believe he’s in way over his head. Valeant has severely damaged its reputation with investors across the globe, and I don’t believe anything can reverse what has already happened.

As Warren Buffett once said, “It takes 20 years to build a reputation and five minutes to ruin it.”. To say Valeant’s reputation has been ruined is an understatement.

The company has faced so many scandals and endured so many short attacks that even the most contrarian of investors are avoiding this stock like the plague. Charlie Munger, Warren Buffett’s right-hand man, even went as far as to call the company a “sewer.” These are strong words put forth by the guru, but I believe he’s right on the spot with his statement.

There are many contrarian investors that are looking to gain a quick profit by trying to get into Valeant. But there doesn’t appear to be a bottom, and the upside may be limited considering the company’s ruined reputation.

Activist investor Bill Ackman is now on the board of directors, and he’s still fully invested, even after the massive decline the stock faced over the past year and a half. Don’t follow Ackman into this one. Most of his original investment is already gone, and he’s just trying to recover some of his losses, but I don’t believe he’ll be successful.

Valeant still has $8 billion worth of debt and will need to sell its non-core assets at a loss. Buying high and selling low is never a good strategy to make money, and I believe the company will remain on damage control for the next few years before the stock can start moving higher.

Even if you’re a believer in Bill Ackman and the new CEO Joseph Papa, any upside in 2017 will be very modest, and there’s still the risk of a further correction as more disappointing earnings reports come in. There is also the risk of having more scandals should there be any shady findings from investigations going forward.

If you’re a contrarian investor, then steer clear of Valeant. Its reputation is permanently damaged, and it’s not going to soar anytime soon. There’s still a huge mess that Michael Pearson left, and it won’t be cleaned up anytime soon.

I have one simple rule. If there’s any sign of shady activity in a company’s history, then that makes the stock an automatic sell. Don’t even think about picking up share in Valeant unless you’re willing to lose it all.

Fool contributor Joey Frenette has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »